Multidrug Resistant Bacteria Market Size and Forecast 2024-2033| Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG

Overview and Scope

Multidrug-resistant bacteria refer to strains of bacteria that have developed resistance to multiple types or classes of antibiotics. These bacteria are no longer susceptible to the effects of several different antibiotics that would typically be effective in treating bacterial infections. Multidrug-resistant organisms tend to occur in hospitals and medical care facilities when antibiotics are used for longer than necessary or when they are not needed.

Sizing and Forecast

The multidrug resistant bacteria market size has grown strongly in recent years. It will grow from $11.86 billion in 2023 to $12.61 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to antibiotic resistance crisis, advancements in drug discovery, regulatory incentives, public health initiatives.

The multidrug resistant bacteria market size is expected to see strong growth in the next few years. It will grow to $16.22 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to antibiotic stewardship programs, global spread of resistance, phage therapy and alternative treatments, public and private investment. Major trends in the forecast period include precision medicine for infectious diseases, combination therapies, continuous surveillance and monitoring, global collaboration.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report

Segmentation & Regional Insights

The multidrug resistant bacteria market covered in this report is segmented –

1) By Disease: Urinary Tract Infection; Intra-Abdominal Infections; Blood Stream Infections; Clostridium Difficile Infections; Acute Bacterial Skin And

Skin Structure Infections; Hospital Acquired Bacterial Pneumonia; Acquired Bacterial Pneumonia; Other Diseases

2) By Drug Class: Oxazolidinones; Lipoglycopeptides; Tetracyclines; Cephalosporins; Combination Therapies; Other Drug Classes

3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

North America was the largest region in the multidrug-resistant bacteria market in 2023. The regions covered in multidrug-resistant bacteria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13044&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of infectious diseases is expected to propel the growth of the multidrug-resistant bacteria market going forward. Infectious diseases refer to illnesses brought on by harmful microorganisms, such as bacteria, viruses, fungi, or parasites. Multidrug-resistant bacteria are closely associated with infectious diseases due to their ability to cause infections that are difficult to treat using conventional antibiotics. These bacteria have developed resistance to multiple antibiotics, making them less susceptible to the medications commonly used to combat bacterial infections. For instance, in July 2022, according to data released by the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, the number of notifiable infectious diseases in Australia increased from 289,013 in 2020 to 701,820 in 2021. Therefore, the increasing prevalence of infectious diseases will drive the multidrug-resistant bacteria market.

Key Industry Players

Major players in the multidrug resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.

The multidrug resistant bacteria market report table of contents includes:

1. Executive Summary

2. Multidrug Resistant Bacteria Market Characteristics

3. Multidrug Resistant Bacteria Market Trends And Strategies

4. Multidrug Resistant Bacteria Market – Macro Economic Scenario

5. Global Multidrug Resistant Bacteria Market Size and Growth

26. South America Multidrug Resistant Bacteria Market

27. Brazil Multidrug Resistant Bacteria Market

28. Middle East Multidrug Resistant Bacteria Market

29. Africa Multidrug Resistant Bacteria Market

30. Multidrug Resistant Bacteria Market Competitive Landscape And Company Profiles

Top Major Players: